UnitedHealth Stock Ran On A Repricing The Company Described In Advance

The lever behind UnitedHealth stock’s climb was a Medicare Advantage repricing management had described months before the run began, and the hard part was believing a plan whose author had just been wrong.

UnitedHealth (UNH) has returned 66% over the past year, moving from $254.26 to $421.47, against 17.7% for the S&P 500. Managed care did not move as a block: CVS returned 81% over the same stretch, ELV 33%, and CI 0.6%. A sector tide does not produce that spread, so the explanation is company by company. The odd part is how plainly this company had described its own.

The Run Was Paying For Margin, Not Growth

Its second quarter 2026 report shows it cleanly. Revenue of $112 billion was roughly flat year over year, while operating earnings of $8 billion grew 55%. Adjusted earnings per share came in at $6.38 against $4.08 a year earlier. The medical care ratio, the share of premiums paid out as care, was 87% against 89% in the second quarter of 2025. Management raised its full year 2026 adjusted earnings guidance to $19.50 to $20 a share and credited the pricing, benefit design and market actions it had taken over the prior twelve months.

The improvement at UnitedHealthcare came from Medicare Advantage, and the trade behind it shows in membership: the company now expects Medicare Advantage enrollment to fall by roughly 1.1 million across full year 2026, with Medicare margins finishing above 3%. It is covering fewer people at better margins. That is a pricing decision, not a demand surprise.

That Pricing Decision Was Described In April 2025

More than three months before the run began, the company had named both the diagnosis and the fix. In its Medicare Advantage business, it had planned for 2025 care activity to rise in line with 2024 and found it rising at twice that rate. By management’s own account at the time, plan designs and pricing for 2026 would be built around those elevated trends. The pricing assumption was that the elevated activity would persist through 2025 and into 2026, and on that basis Medicare could return to the historical planning margin targets the company had always used.

The financials underneath the fear argued the same way. As of the fiscal Q1 2025 results, the last quarterly report made public before the run began, trailing revenue was $410.06 billion, growing 8.1% against an average of 11.3% a year across the prior three fiscal years. Trailing operating margin was 8.2% versus a three-year average of 8.5%, and trailing net margin was 5.4%, slightly above its 5.2% three-year average though below a 6.2% peak. On that base, the damage read as a pricing gap, not a broken franchise.

Elevated Volatility And A Negative Credit Outlook Argued For Caution

None of that made the position comfortable. Implied volatility on UNH options sat in the 91st percentile of its own trailing year in mid-June 2025 and still in the 90th percentile in mid-July 2025, at a reading of 37.8. That is a market braced for a large move in either direction and silent on which one. In early June 2025 AM Best revised its outlooks on the company to negative from stable while affirming its ratings, so the outside credit read was moving the other way.

Legible In Advance, But Only If You Underwrote The Plan

So the signs were real, with a condition attached. This was not a buried data point but a stated plan, and acting on it meant underwriting management’s execution at the moment its own numbers had failed. The repair is still uneven: commercial cost trend is running modestly above the 11% level the company had been seeing, and management now expects full commercial margin recovery to take past 2027. The second quarter 2026 medical care ratio also carried $860 million of net favorable prior period development, which flatters the comparison. The transferable lesson is narrower than the return: when a company tells you which prices it is resetting and for which year, that is the signal, whatever the credit outlook says at the time. The pattern you can screen for, rather than name afterwards, is a rising outlook meeting momentum.

A Repriced Book Can Be Repriced Against You

Nothing above argues the run must continue, or must end. It argues that the gain came from a pricing reset inside a business whose underlying cost trend, by management’s own account, has not inflected and remains very high against historical levels. Holding that deliberately is reasonable. Holding it as the position that decides your year is another matter. A rules-based portfolio sizes a name like this in advance and rebalances on a schedule rather than on the last report, which is the idea behind the Trefis High Quality portfolio. The Trefis High Quality (HQ) Portfolio has a track record of outpacing a benchmark that combines the three major indices – the S&P 500, S&P Mid-cap, and Russell 2000.